LRRK2 inhibitors may combat Parkinson’s progression

An enzyme closely associated with genetic forms of Parkinson’s disease appears to play a larger role in its progression than previously thought, say investigators. The new research offers encouraging evidence that drugs to block this enzyme, known as leucine-rich repeat kinase 2 or LRRK2, could slow — or even prevent — Parkinson’s from developing.

READ FULL ARTICLE From Science Daily